Budget Impact and Incremental Survival Benefit of Using Lenvatinib as a Treatment for Radioactive Iodine Refractory Differentiated Thyroid Cancer in Russia
Value in Health - United Kingdom
doi 10.1016/j.jval.2016.03.1552
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2016
Authors
Publisher
Elsevier BV